ARMISARTE Concentrate for solution for infusion Ref.[8457] Active ingredients: Pemetrexed

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Actavis Group PTC ehf., Reykjavíkurvegi 76-78, 220 Hafnarfjörður, Iceland

Product name and form

Armisarte 25 mg/ml concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

The concentrate is clear, colourless to slightly yellowish or yellow-greenish solution.

The pH is between 7.0 and 8.0.

Qualitative and quantitative composition

One ml of concentrate contains 25 mg pemetrexed (as pemetrexed diacid).

One vial of 4 ml concentrate contains 100 mg pemetrexed (as pemetrexed diacid).

One vial of 20 ml concentrate contains 500 mg pemetrexed (as pemetrexed diacid).

One vial of 34 ml concentrate contains 850 mg pemetrexed (as pemetrexed diacid).

One vial of 40 ml concentrate contains 1000 mg pemetrexed (as pemetrexed diacid).

For the full list of excipients see section 6.1.

Active Ingredient Description
Pemetrexed

Pemetrexed is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and and to a lesser extent aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

List of Excipients

Trometamol (for pH adjustment)
Anhydrous citric acid
Methionine
Water for injections

Pack sizes and marketing

Colourless glass vial (type I) with type I rubber (bromobutyl) serum stopper and an aluminium cap with polypropylene disk. Vials may or may not be sheathed in a protective sleeve.

Pack sizes:

1 × 4 ml vial (100 mg/4 ml)
1 × 20 ml vial (500 mg/20 ml)
1 × 34 ml vial (850 mg/34 ml)
1 × 40 ml vial (1000 mg/40 ml)

Not all pack sizes may be marketed.

Marketing authorization holder

Actavis Group PTC ehf., Reykjavíkurvegi 76-78, 220 Hafnarfjörður, Iceland

Marketing authorization dates and numbers

EU/1/15/1063/001
EU/1/15/1063/002
EU/1/15/1063/003
EU/1/15/1063/004

Date of first authorisation: 18 January 2016

Drugs

Drug Countries
ARMISARTE Austria, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.